Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly &...